Acuson turns in strong financials

Article

Ultrasound vendor Acuson of Mountain View, CA, released year-end financial results this month that showed double-digit growth in revenues and net income. The company credited the performance to momentum generated by its Sequoia and Aspen products, as

Ultrasound vendor Acuson of Mountain View, CA, released year-end financial results this month that showed double-digit growth in revenues and net income. The company credited the performance to momentum generated by its Sequoia and Aspen products, as well as a robust U.S. market.

For the year (end-December), Acuson had revenues of $437.8 million, up 26% compared with $346.2 million in 1996. The vendor's net income for the year was $22.4 million, compared with a net loss of $10.6 million in 1996, when costs associated with the Sequoia and Aspen launches sent the company into the red.

For the fourth quarter, Acuson's sales were $117.4 million, up 25% over the same period the year before, when the company recorded $93.7 million in revenues. Net income for the most recent period was $6.3 million, compared with a net loss of $2.9 million in the fourth quarter of 1996.

Acuson achieved the revenue growth despite weakness in the Asian and European markets, according to chairman and CEO Samuel Maslak. Market conditions remain positive in 1998, with the U.S. market showing continued strength and the European market stabilizing. Asia will continue to experience difficulties in 1998, but the company remains committed to expansion in the region, Maslak said.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.